To develop a novel tool to increase the number of prostate cancer (PCa) patients eligible for active surveillance (AS) without increasing the risk of unfavourable pathologic features (i.e., misclassification) at radical prostatectomy (RP).
Neoadjuvant chemotherapy (NAC) has been increasingly adopted in the management of high-grade upper tract urothelial carcinoma (UTUC), largely extrapolating from level I evidence in urothelial carcinoma of the bladder.
To evaluate whether urothelial carcinoma with sarcomatoid differentiation is associated with a lower pathologic response rate to neoadjuvant chemotherapy and worse oncologic outcomes compared to urothelial carcinoma without variant histology among patients undergoing radical cystectomy.
Login to update email address, newsletter preferences and use bookmarks.
Email
Password